Completed OBSERVATIONAL NCT01050634

Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST) (FAST)

Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST) a Non-interventional Trial With Aromasin®

Sponsor: Pfizer

Conditions Post Menopausal Women With Early Breast Cancer

Interventions Aromasin (exemestane)

Updated 7 times since 2017 Last updated: Jun 23, 2010 Started: Nov 30, 2005 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Post Menopausal Women With Early Breast Cancer, this trial is completed. The trial is conducted by Pfizer and has accumulated 7 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 2 earlier versions

Feb 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.